Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer
Launched by SYDNEY CHILDREN'S HOSPITALS NETWORK · May 24, 2021
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective family-based whole-genome sequencing (WGS) is in identifying genetic factors that may increase the risk of cancer in children and young adults who have just been diagnosed with cancer. Whole-genome sequencing is a test that looks at all of a person's DNA to find any changes that could lead to cancer. The goal is to see if this type of testing can help doctors understand why a child has cancer and if other family members might also be at risk.
To be eligible for the trial, participants must be 21 years old or younger and have a new diagnosis of cancer. Parents or caregivers of these young patients can also take part in the study, along with healthcare professionals who care for them. Participants can expect to undergo genetic testing and may receive information that could help them and their families understand cancer risks better. This study is currently recruiting participants, and it aims to provide valuable insights that could improve cancer care for young patients and their families.
Gender
ALL
Eligibility criteria
- • New diagnosis of malignancy
- • Age ≤ 21 years
- • Written informed consent
- Psychosocial component:
- • Participants (≥ 12 years)
- • Parent/caregiver(s) of participants
- • Healthcare professionals involved in the care of patients enrolled in the study
About Sydney Children's Hospitals Network
Sydney Children's Hospitals Network (SCHN) is a leading pediatric healthcare organization dedicated to advancing child health through innovative clinical research and trials. Comprising multiple facilities, including the Children's Hospital at Westmead and Sydney Children's Hospital, Randwick, SCHN is committed to delivering high-quality care while fostering a dynamic research environment. The network collaborates with various stakeholders, including academic institutions and healthcare organizations, to enhance the understanding of pediatric diseases and improve treatment outcomes. With a focus on ethical practices and patient safety, SCHN aims to translate research findings into clinical practice, ultimately benefiting children and families across Australia and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sydney, New South Wales, Australia
Newcastle, New South Wales, Australia
Sydney, New South Wales, Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials